ATEC at a glance
Alphatec Holdings, Inc. (ATEC, SEC CIK 1350653) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Alphatec Holdings, Inc. (ATEC) reported revenue of $764.2 million (up 25.0% from FY2024) and a net loss of $143.4 million. Diluted EPS was -$0.96.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Alphatec Holdings, Inc. (ATEC) shares worth $345.7 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Miles Patrick on September 10, 2026 of 115,000 shares at $8.81 per share.
- In the last 90 days, ATEC insiders reported 1 open-market purchase ($1.0M) and 1 open-market sale ($79K) on Form 4, a net purchase of $934K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $764.2M
- +25.0% vs prior year
- Insiders · 90 days
- 1 buy · 1 sell
- Net +$934K
- 13F holders
- 31 funds
- $345.7M · −1 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Design, manufacture, and sale of spinal surgery medical devices, with polyaxial pedicle screw systems accounting for ~38% of net sales in 2025
- No new products or segments introduced; emphasis on risks related to existing polyaxial pedicle screw systems and licensing compliance
- Strategic focus on managing global regulatory compliance, supply chain risks including tariffs, and AI technology use to mitigate operational and legal risks
- Liquidity: $160.8 million cash and equivalents at year-end 2025; reliance on subsidiaries’ dividends for holding company cash needs emphasized
- Noteworthy risk disclosures on potential natural disasters impacting nearly all operations in wildfire and earthquake zones, and heightened legal/regulatory scrutiny including healthcare laws and intellectual property litigation
Risk Factors
- Litigation settlement and ongoing matters increased litigation-related expenses 143% to $23.8M in 2025
- Exposure to foreign currency exchange risk as international business outside U.S. grows
- Inventory purchase commitment with third-party supplier of $5.0M remaining through December 2025
- Market share challenged by surgeons’ adoption and expansion of competing spine surgery technologies
- $405M principal 0.75% senior convertible notes due 2030 with complex conversion features and capped call hedges
Management Discussion & Analysis
- Forward-looking risks include operating losses, future revenue, expenses, liquidity, and need for additional funding
- Key regulatory challenges: compliance with FDA and international quality requirements
- Business risks: market acceptance, product commercialization, sales network maintenance, and talent retention
- Economic and geopolitical factors, plus public health crises, may materially affect future results
AI summary of the ATEC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $213.5M, up 15% from $185.5M YoY, driven by product volume and surgeon adoption
- Cost-of-sales margin 72.2% vs 69.6% YoY, based on revenue and cost-of-sales figures
- Operating margin 27.0% vs 23.3% YoY, based on revenue, cost of sales, and operating expenses
- Best-performing driver: product volume from expanded surgeon base and new product portfolio, supporting $28.0M revenue growth
- Cash $118.7M vs $160.8M at December 31; operating cash flow $21.8M and investing outflows $42.6M
- New JPM facilities: $175.0M term loan and $40.0M revolver outstanding; liquidity deemed adequate, with risks from operating losses and potential additional funding needs
Risk Factors
- No Risk Factors section provided; submitted text covers unregistered securities, trading arrangements, warrants, and exhibits
- New credit agreement dated May 1, 2026, indicating changed financing arrangements
- Amended warrant expiration extended to December 31, 2030, increasing potential future equity dilution
- 2026 Equity Incentive Plan approved June 10, 2026, adding stock-option and RSU award mechanisms
- Unregistered issuances totaled 51,617 shares during the quarter, creating incremental dilution exposure
AI summary of the ATEC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal period ended June 30, 2026; results announced August 4, 2026
- Detailed financial results contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q2 revenue $214M, up 15% year-over-year, with surgical revenue $196M, up 17% on 20% case-volume growth
- Adjusted EBITDA $36M, margin 16.8%, expanding 420 basis points year-over-year
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Shareholders approved the 2026 Equity Incentive Plan, enabling continued equity-based compensation and potential dilution
- Shareholders approved the 2026 Employee Stock Purchase Plan, supporting employee share ownership and retention
Item 5.07: Submission of Matters to a Vote of Security Holders
- All seven director nominees elected to one-year terms ending at the 2027 Annual Meeting
- 2026 Equity Incentive Plan approved, authorizing expanded stock-based compensation capacity
Item 1.02: Termination of a Material Definitive Agreement
- Prior Credit Agreements terminated May 1, 2026 upon entry into a new Credit Agreement
- All outstanding principal, accrued interest and applicable fees fully repaid
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 results for period ended March 31, 2026
- Press release with financial details attached as Exhibit 99.2
Item EX-99.1: Item EX-99.1
- New $300M bank facility: $125M revolver plus $175M Term Loan A
- Refinances existing Braidwell, Pharmakon, and MidCap debt, simplifying ATEC’s capital structure
AI summaries of ATEC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ATEC
Don't miss the next ATEC filing
- Alerts as it files. A push when ATEC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ATEC, by share count.
- Ask anything. An AI agent that reads every ATEC filing and answers with sources.
ATEC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Carls Thomas Andrew | A | Oct 5, 2026 | 200,000 | - |
| Miles Patrick | Buy | Sep 10, 2026 | 115,000 | $8.81 |
| Marshall Tyson Eliot | Sell | Aug 5, 2026 | 8,168 | $9.65 |
| MCGINNIS KAREN K | Sell | Jun 11, 2026 | 6,050 | $8.01 |
| Demski David M | A | Jun 10, 2026 | 32,012 | - |
| MCGINNIS KAREN K | A | Jun 10, 2026 | 32,012 | - |
| Blackford Quentin S. | A | Jun 10, 2026 | 32,012 | - |
| Valentine Keith | A | Jun 10, 2026 | 32,012 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $611.6M | $764.2M |
| Gross Profit | - | $424.3M | $531.9M |
| Operating Income | - | -$136.2M | -$82.1M |
| Net Income | - | -$162.1M | -$143.4M |
| Gross Margin | - | 69.4% | 69.6% |
| Op. Margin | - | -22.3% | -10.7% |
| Net Margin | - | -26.5% | -18.8% |
| Balance Sheet | |||
| Total Assets | $805.2M | $775.7M | $791.2M |
| Equity | $78.1M | -$14.2M | $12.4M |
| ROE | - | 1144.2% | -1153.7% |
| Per Share | |||
| EPS | - | $-1.13 | $-0.96 |
| Cash Flow | |||
| Operating CF | - | -$44.7M | $45.2M |
| CapEx | - | $83.2M | $42.5M |
Source: XBRL data in Alphatec Holdings, Inc. (ATEC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ATEC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $345.7M |
| Q1 2026 | 32 | $412.2M |
| Q4 2025 | 31 | $846.8M |
| Q3 2025 | 30 | $540.7M |
| Q2 2025 | 26 | $354.5M |
| Q1 2025 | 23 | $203.3M |
| Q4 2024 | 19 | $130.2M |
| Q3 2024 | 14 | $60.0M |
- Citadel Advisors LLC+1.60M (+187%)
- BlackRock+1.24M (+12%)
- AQR Capital Management+1.00M (+72%)
- FMR LLC (Fidelity)+638.3K (+222%)
- Raymond James Financial+634.0K (+63%)
- Millennium Management−1.66M (-59%)
- Two Sigma Investments−1.22M (-60%)
- Renaissance Technologies LLC−770.6K (-73%)
- Bank of America Corp−584.4K (-23%)
- Morgan Stanley−115.8K (-7%)
- Allstate+70.6K
- D.E. Shaw & Co−18.5K
- PARK NATIONAL CORP /OH/−10.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 206 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ATEC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 10-K | Feb 24, 2026 | Dec 31, 2025 | Analysis |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
ATEC SEC filings: frequently asked questions
Are ATEC insiders buying or selling?
In the last 90 days, Alphatec Holdings, Inc. (ATEC) officers, directors and 10% owners reported 1 open-market purchase worth $1.0 million by 1 insider and 1 open-market sale worth $78,821 by 1 insider on Form 4, a net purchase of $934,329. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ATEC stock?
As of June 30, 2026, the largest Alphatec Holdings, Inc. (ATEC) holders among the 13F filers tracked by SignalX were BlackRock ($98.0 million), Vanguard Capital Management LLC ($44.3 million), State Street Corp ($30.1 million), Citadel Advisors LLC ($21.3 million), AQR Capital Management ($20.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ATEC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Alphatec Holdings, Inc. (ATEC) reported revenue of $764.2 million (up 25.0% from FY2024) and a net loss of $143.4 million. Diluted EPS was -$0.96. The figures come from the XBRL data in the 10-K.
What are the main risks in ATEC's latest 10-K?
In the 10-K filed February 24, 2026, Alphatec Holdings, Inc. (ATEC) flagged: Litigation settlement and ongoing matters increased litigation-related expenses 143% to $23.8M in 2025. Exposure to foreign currency exchange risk as international business outside U.S. grows. (AI summary of the Risk Factors section.)
What did ATEC report in its latest 8-K?
Alphatec Holdings, Inc. (ATEC) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal period ended June 30, 2026; results announced August 4, 2026.
What are the latest ATEC SEC filings?
Alphatec Holdings, Inc. (ATEC) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on October 5, 2026.
What is ATEC's SEC CIK number?
Alphatec Holdings, Inc. (ATEC)'s SEC Central Index Key (CIK) is 1350653. EDGAR lists every ATEC filing under that number.
Ask anything about ATEC
The research agent reads ATEC's filings, financials, insider trades and 13F holders, then answers with sources.